Equities

CannaPharmaRx Inc

CPMD:PKC

CannaPharmaRx Inc

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (USD)0.0088
  • Today's Change0.00 / 0.00%
  • Shares traded111.20k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.000.000.03
Total Receivables, Net0.060.020.00
Total Inventory1.13----
Prepaid expenses00.070
Other current assets, total00.01--
Total current assets1.200.100.03
Property, plant & equipment, net6.035.240.01
Goodwill, net------
Intangibles, net------
Long term investments4.520.080.08
Note receivable - long term------
Other long term assets------
Total assets125.410.11
LIABILITIES
Accounts payable------
Accrued expenses0.900.340.38
Notes payable/short-term debt7.018.939.02
Current portion long-term debt/capital leases------
Other current liabilities, total1.471.010.51
Total current liabilities181713
Total long term debt05.590
Total debt7.01159.02
Deferred income tax------
Minority interest------
Other liabilities, total5.7300
Total liabilities242313
SHAREHOLDERS EQUITY
Common stock0.040.030.01
Additional paid-in capital767573
Retained earnings (accumulated deficit)(91)(95)(86)
Treasury stock - common0.000.000.00
Unrealized gain (loss)------
Other equity, total(0.04)0.24(0.37)
Total equity(12)(17)(13)
Total liabilities & shareholders' equity125.410.11
Total common shares outstanding435274125
Treasury shares - common primary issue6.230.130.13
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.